This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Coherus BioSciences Inc (CHRS)

NASDAQ: Health Care

Company Income Statement
Dec 2014 Dec 2013
Sales 31.11M 2.75M
Cost of Sales 0.00 0.00
Gross Operating Profit 31.11M 2.75M
Selling, General, and Administrative Expenses 17.56M 7.46M
Research & Development 78.22M 31.28M
Operating Income before D & A (EBITDA) -64.68M -35.99M
Depreciation & Amortization 4.57M 404.00K
Interest Income 0.00 0.00
Other Income - Net -18.59M -12.35M
Special Income / Charges 0.00 0.00
Total Income Before Interest Expenses (EBIT) -87.85M -48.75M
Interest Expense 3.90M 5.29M
Pre-Tax Income -91.75M -54.04M
Income Taxes 0.00 0.00
Minority Interest -44.00K 0.00
Net Income From Continuing Operations -87.18M -53.63M
Net Income From Discontinued Operations 0.00 0.00
Net Income From Total Operations -87.18M -53.63M
Extraordinary Income/Losses 0.00 0.00
Income From Cum. Effect of Acct. Change 0.00 0.00
Income From Tax Loss Carryforward 0.00 0.00
Other Gains / Losses 0.00 0.00
Total Net Income -87.13M -53.63M
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
-87.18M -53.63M
Preferred Dividends
Net Income Available To Common -87.18M -53.63M
Basic EPS from Continuing Ops. -10.64 -2.80
Basic EPS from Discontinued Ops. 0.00 0.00
Basic EPS from Total Operations -10.64 -2.80
Basic EPS from Extraordinary Inc. 0.00 0.00
Basic EPS from Cum Effect of Accounting Change 0.00 0.00
Basic EPS from Tax Loss Carryf'd. 0.00 0.00
Basic EPS from Other Gains (Losses) 0.00 0.00
Basic EPS, Total -10.64 -2.80
Basic Normalized Net Income/Share -10.64 -2.80
EPS fr Continuing Ops. -10.64 -2.80
EPS fr Discontinued Ops 0.00 0.00
EPS fr Total Ops. -10.64 -2.80
EPS fr Extraord. Inc. 0.00 0.00
EPS fr Cum Effect of Accounting Change 0.00 0.00
EPS fr Tax Loss Carfd. 0.00 0.00
EPS fr Other Gains (L) 0.00 0.00
EPS, Total -10.64 -2.80
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
-10.64 -2.80
Dividends Paid per Share 0.00 0.00

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

CHRS Coherus BioSciences Inc

Chart of CHRS

Analysts Ratings for CHRS

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 3 2 2 2
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0

CHRS Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs